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To the Editor:
Whole brain irradiation (WBI) is 
the standard of treatment for brain metas-
tases in anaplastic lymphoma kinase 
(ALK)-positive lung cancer. However, it is 
difficult to treat such tumor that is refrac-
tory on WBI. Here, we presented a case 
effectively control of intracranial metas-
tases by bevacizumab and chemotherapy.
CASE PRESENTATION
A 58-year-old never-smoking female 
presented with 2 weeks of persistent 
dizziness, headache, and unsteady gait. 
Computed tomography (CT) of chest on 
September 3, 2013 showed a 3.1 × 2.7 cm 
spiculated mass over left lower lung 
(LLL) that invaded to pleura and peri-
cardium with ipsilateral hilar lymphade-
nopathy (Fig. 1A). Magnetic resonance 
imaging (MRI) of brain revealed mul-
tiple enhanced intracranial lesions with 
perifocal edema (Fig. 1B and C). The 
result of bronchoscopic biopsy proved 
lung adenocarcinoma. No activating epi-
dermal growth factor receptor (EGFR) 
mutation was identified by Scorpions 
ARMS. The immunohistochemistry 
staining for ALK showed strongly posi-
tive by Ventana autostainer system.
The patient started chemo-
therapy with triweekly pemetrexed 
(500 mg/m2) and cisplatin (60 mg/m2) 
after 2 weeks of WBI completed on 
October 18, 2013. After two courses 
of chemotherapy administered, she 
suffered from acute left lower leg 
weakness with focal myoclonic jerks 
on November 23. Magnetic reso-
nance imaging of brain demonstrated 
enlarged all intracranial metastases 
with significant peri-tumor edema (Fig. 
1E and F). On the other hand, com-
puted tomography of chest revealed 
primary lung tumor regressed (Fig. 
1D). To control intracranial metas-
tases, we administered bevacizumab 
(5 mg/kg) on day 1 with pemetrexed 
and cisplatin on day 2 every 3 weeks 
to normalize tumor vasculature and 
improve drug delivery. The follow-up 
imaging showed regression of intra-
cranial tumors with decreased periph-
eral enhancement and edema (Fig. 1H 
and J), as well as primary lung tumor 
continuing shrinked (Fig. 1G). Her 
symptoms resolved completely. The 
patient has continued on treatment for 
8 months more without any neurologic 
adverse effects.
DISCUSSION
Intracranial metastasis is frequent in 
ALK-positive lung cancer patients, 
either for those untreated or on crizo-
tinib treatment.1 Most of ALK-positive 
lung cancer with brain metastasis 
response well to WBI.2 For patients 
with progressive central nervous system 
(CNS) metastasis on crizotinib or radio-
therapy, several next-generation ALK 
inhibitors showed a promising activity 
for CNS penetration and intracranial 
disease control.3 However, in the area 
lacks of reimbursement of crizotinib 
and no available new ALK inhibitors, 
it is very difficult to treat an ALK-
positive, radioresistant brain metastasis 
patients. Bevacizumab, a humanized 
anti-vascular endothelial growth fac-
tor (VEGF) antibody, previously had 
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FIGURE 1.  Representative image series from initial diagnosis (A–C), intracranial 
progression (D–F), and disease regression (G–I). A, A spiculated Left lower lung (LLL) 
mass in nonenhanced CT. B and C, T1 postgadolinium showed multiple intracranial 
metastases over right vermis, left posterior temporal, and frontal area. D, Left lower 
lung (LLL) tumor regressed after pemetrexed/cisplatin treatment. E and F, T2 FLAIR 
showed enlarged brain metastases with significant perifocal edema. G–I, Regression 
of primary tumor as well as intracranial metastases after adding bevacizumab to 
pemetrexed/cisplatin. CT, computed tomography.
LETTER TO THE EDITOR
e22 Copyright © 2015 by the International Association for the Study of Lung Cancer
Letter to the Editor Journal of Thoracic Oncology ®  •  Volume 10, Number 4, April 2015
shown a great antitumor activity and 
good safety profiles for non–small-lung 
cancer patients, even for those with CNS 
metastasis.4 Several preclinical studies 
indicated bevacizumab lead to tumor 
vessels normalization and reduced 
interstitial fluid pressure that increased 
the delivery of cytotoxic chemotherapy. 
Lu et al.5 presented promising CNS 
response of BEEP (bevacizumab, eto-
poside, cisplatin) regimen for breast 
cancer patients with brain metastases 
refractory to WBI. Nine of 12 evaluable 
patients (75%) achieved CNS response, 
including six patients (50%) had greater 
than or equal to 80% CNS tumor volu-
metric reduction. In this case, on the 
basis of pemetrexed and cisplatin effec-
tively controlled extracranial lesions, 
we added bevacizumab to increase 
CNS control successfully. The efficacy 
of bevacizumab-contained regimen 
for ALK-positive-radioresistant brain 
metastasis is worthy to study in further 
prospective trials.
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